NitiLoop

Company Overview

Snapshot

Founded in January 2011, NitiLoop operates with 1–10 employees. The company was acquired by Microbot Medical in October 2022.

Business overview

NitiLoop develops vascular support microcatheters, with its core product, NovaCross, designed to facilitate guidewire positioning and provide distal support in medical procedures. The NovaCross system incorporates an operator-controlled nitinol scaffold and an extendable segment at its distal tip. NitiLoop's proprietary platform extends to additional products for below-the-knee and embolotherapy applications, including the treatment of liver cancer with chemotherapy and the injection of radiation beads. The company serves the healthcare industry, specifically within the medical devices, cardiology, and cardiovascular sectors.

Strategic signal

In October 2022, NitiLoop was acquired by Microbot Medical, marking a significant exit for the company. This acquisition indicates a strategic consolidation within the medical device sector, with Microbot Medical integrating NitiLoop's FDA-cleared microcatheter technology to strengthen its own robotic system portfolio. For investors, this signals the value and market demand for innovative vascular support solutions and highlights a successful exit strategy in the health tech and life sciences domain.

Company Intelligence Q&A

What is NitiLoop's primary product?

NitiLoop's primary product is the NovaCross microcatheter, designed for vascular support to enable guidewire positioning and provide distal support with an extendable segment.

When did NitiLoop receive FDA 510(k) clearance for its NovaCross Microcatheter?

NitiLoop announced FDA 510(k) clearance for its NovaCross Microcatheter in May 2015, for supporting guidewire access to discrete regions of the coronary and peripheral vasculature.

When was NitiLoop acquired?

NitiLoop was acquired by Microbot Medical in October 2022.

What was the strategic importance of NitiLoop's acquisition by Microbot Medical?

The acquisition by Microbot Medical in October 2022 allowed Microbot Medical to strengthen its Liberty Robotic System portfolio by integrating NitiLoop's novel, FDA-cleared devices, including its microcatheters.

When did NitiLoop's NovaCross earn FDA clearance for treating Chronic Total Occlusion (CTO)?

In April 2020, NitiLoop's NovaCross earned FDA clearance for treating Chronic Total Occlusion (CTO) prior to PTCA or stent intervention.